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Abstract: Research suggests an overrepresentation of autism spectrum diagnoses (ASD) or autistic
traits in gender diverse samples, particularly in children and adolescents. Using data from the
GENTLE (GENder identiTy Longitudinal Experience) Cohort at the Gender Diversity Service at
the Perth Children’s Hospital, the primary objective of the current retrospective chart review was
to explore psychopathology and quality of life in gender diverse children with co-occurring ASD
relative to gender diverse children and adolescents without ASD. The Social Responsiveness Scale
(Second Edition) generates a Diagnostic and Statistical Manual of Mental Disorders (DSM-5) score
indicating a likely clinical ASD diagnosis, which was used to partition participants into two groups
(indicated ASD, n = 19) (no ASD indicated, n = 60). Indicated ASD was far higher than would be
expected compared to general population estimates. Indicated ASD on the Social Responsiveness
Scale 2 (SRS 2) was also a significant predictor of Internalising behaviours (Anxious/Depressed,
Withdrawn/Depressed, Somatic Complaints, Thought Problems subscales) on the Youth Self Report.
Indicated ASD was also a significant predictor of scores on all subscales of the Paediatric Quality
of Life Inventory. The current findings indicate that gender diverse children and adolescents with
indicated ASD comprise an especially vulnerable group that are at marked risk of mental health
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difficulties, particularly internalising disorders, and poor quality of life outcomes. Services working
with gender diverse young people should screen for ASD, and also provide pathways to appropriate
care for the commonly associated mental health difficulties.
Keywords: gender diverse; transgender; autism; ASD
1. Introduction
The past decade has seen increasing clinical and empirical interest in the co-occurrence of gender
diversity and autism spectrum disorders (ASD). Gender diversity is an umbrella term used to describe
an evolving range of labels (e.g., non-binary, transgender, agender) that individuals may apply when
their gender identity, expression or behaviours do not conform to the norms and stereotypes of their
sex assigned at birth) [1]. While clinically significant distress associated with this incongruence is
referred to as gender dysphoria [2], the spectrum of gender diversity is increasingly recognised as a
normal part of human variation. ASD, according to the Diagnostic and Statistical Manual of Mental
Disorders (DSM-5), comprises a group of early-onset neurodevelopmental disorders characterised
by persistent deficits in social communication skills across multiple contexts, in addition to restricted
and/or repetitive interests and behaviours [2]. The broader spectrum of ASD traits is also recognised as
part of normal human diversity [3].
Research suggests an overrepresentation of ASD diagnoses or autistic traits in gender diverse
samples, particularly in children and adolescents [4–8], compared to the general population [9,10].
For example, data from Trans Pathways, the largest study conducted in Australian trans and
gender-diverse young people (n = 859; mean age = 19.4), found that 22.5% of the sample reported having
received a formal ASD diagnosis, while more than one third (35.2%) warranted further diagnostic
assessments to clarify whether ASD was present [11]. Causal underpinnings of this co-occurrence
remain poorly understood, and while theories have been postulated (see Van Der Miesen & Colleagues
for a review of underlying hypotheses [12]), a robust evidence base is lacking. Gender diverse
behaviours and interests in children and adolescents with ASD may be dismissed by families and
clinicians as issues that are part of the ASD phenotype (i.e., restricted, repetitive interests that are
unusual in focus). However, the clinical consensus is that in most cases, gender diverse identities and
behaviours are not secondary to ASD but co-occur as an aspect of personal identity [13–16].
There has recently been a surge in referrals to specialised child and adolescent gender clinics
generally, both within Australia and internationally [1,17–20]. Gender diverse young people and their
families present to these services for a number of reasons, including multidisciplinary assessment and
support, but often to explore eligibility and wishes for hormonal interventions, including puberty
suppression (e.g., gonadotropin-releasing hormone agonists) and/or gender-affirming medications
(e.g., testosterone for those wishing for masculinising effects, and oestrogen for those wishing for
feminising effects) [21,22].
One study estimated that approximately 7.8% of clinic-referred children and adolescents met formal
diagnostic criteria for ASD, as assessed using the Diagnostic Interview for Social and Communication
Disorders-10th Revision [4]. However, rates of ASD amongst child and adolescent gender clinics are
thought to be higher due to the complexity of diagnosis in many cases [13]. ASD diagnoses or traits
do not preclude eligibility for gender-affirming interventions when appropriate. This co-occurrence,
however, is often associated with significant diagnostic and treatment challenges, due to ASD-related
complexities that may be present, such as difficulties with communication, cognitive flexibility,
organization and/or future planning [23].
In light of these considerations, it is important that support and interventions for individuals
with co-occurring gender diversity and ASD or high autistic traits are tailored in accordance with
the young person’s needs, taking individual communication and learning style into account. Where
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the young person is eligible for hormonal intervention, for example, the risks and benefits may need
to be presented in a concrete, literal, detailed manner that caters to the individual’s cognitive skills
to facilitate informed consent. If hormonal treatment is initiated, it may be helpful to commence at
a lower dose and increase the regimen more gradually, particularly if there are ASD-related issues
around hypersensitivity to sensory input and/or difficulties with changes in routine [13].
Awareness of other co-occurring difficulties and/or disorders that may be present in this subgroup
are also critical considerations that can help inform clinical decision-making and improve quality of
life outcomes. These include internalising difficulties (e.g., feelings of anxiety and sadness, etc.) and
externalising difficulties (e.g., hyperactivity, defiance), which may be clinically significant. To our
knowledge, however, there have been no investigations of the psychological profiles or general
quality of life of gender diverse children and adolescents with co-occurring ASD relative to gender
diverse children and adolescents without ASD. Mental health difficulties, including generalised anxiety
disorder, suicidal ideation and intent, and attention-deficit hyperactivity disorder, are significantly
more prevalent in young gender diverse [24–26] and ASD [27–30] groups. In addition, while each
group is exposed to significant levels of stigma and prejudice, gender diverse young people with ASD
experience lower rates of parental support when disclosing concerns around their gender identity,
which may exacerbate distress should they wish to transition socially (which might include a change
in gender pronouns) or medically (via hormonal interventions) [31].
The Gender Diversity Service (GDS), located at the Perth Children’s Hospital, is the only specialised
service in Western Australia to offer support and gender-affirming care to gender diverse children and
adolescents (under the age of eighteen) and their families. In accordance with Clinical Guidelines for
Co-occurring ASD and Gender Dysphoria or Incongruence in Adolescents [13], the GDS screens for
ASD. In addition to clinical interview, the clinic uses the Social Responsiveness Scale 2 (SRS-2) [32],
a 65-item measure that identifies the presence and severity of ASD-specific social impairments and
restricted interests and repetitive behaviours. The SRS-2 also generates a DSM-5 severity score, thereby
providing a metric that reflects the conceptualisation of these symptom categories as described in the
DSM-5. Two child and adolescent gender clinics have used SRS data to examine the distribution of
ASD traits, which indicated that between 44.9% and 54.2% of the respective samples scored outside the
‘normal’ range [16,33]. However, these studies used older versions of the SRS which did not include
the DSM-5 algorithm that indicates the likelihood of a clinical ASD diagnosis.
Drawing from data from the GDS, the primary objective of the current retrospective chart review
was to explore the association between ASD, psychopathology, and quality of life. Using the SRS-2, we
examined the distribution of autistic traits in the GDS sample, with a focus on individuals scoring in
the ‘severe’ range on the DSM-5 subscale as an indicator of ASD. Our secondary aim was to explore
the psychological outcomes and quality of life of participants with indicated ASD compared to those
who were not within the ‘severe’ range on the SRS-2 DSM-5 subscale (no ASD indicated). In light of
existing research [4–8], we hypothesised that a significantly larger proportion of participants would
have indicated ASD compared to estimates from the general population. Similarly, given that ASD and
gender diversity are independent risk factors for psychopathology and lower quality of life outcomes,
it was hypothesised that the indicated ASD group would experience significantly poorer mental health
indices and quality of life, compared to the no ASD indicated group.
2. Methods
2.1. Procedure
The GDS, located at Perth Children’s Hospital in Perth, Western Australia, is a dedicated tertiary
service working with gender diverse children and adolescents and their families. It is an evidence-based,
best-practice tertiary Tier-4 clinical service which provides information, consultation, assessment,
support, and access to puberty suppression and gender-affirming oestrogen or testosterone hormonal
interventions for young people under 18. One hundred and twenty two prospective participant
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families were contacted by the Research Officer, either via phone, letter, or in person prior to individual
clinical appointments at the GDS (for current patients). The purpose of this initial contact was to gauge
interest in their being part of the GENder identiTy Longitudinal Experience (GENTLE) Cohort, of
which the sample for the current study is derived. The GENTLE project seeks to examine medical and
psychological data in patients who have sought intervention and assessment at the GDS for research
purposes, and hence, all patients (past, current and new) are eligible to participate. Families expressing
their interest were booked in to discuss the prospect of consenting their hospital data. Seventeen
participants declined to participate, and 1 decided to withdraw from the Cohort. For the present
study, participants were consented between November 2017 and June 2019. Information from the
appointment closest to intake was collated using the participant’s medical file and mental health files.
All data were de-identified, and the limits of confidentiality were discussed with each participant.
Informed written consent was obtained from each participant before their clinical information could
be accessed for analyses. The Child and Adolescent Health Service Human Research Ethics Committee
have approved the GENTLE Cohort (#RGS320).
2.2. Participants
The final sample was comprised of 104 participants, consisting of all the patients who had given
consent to GENTLE participation and for whom there was a completed SRS-2 parent report measure.
The average age of the sample at referral was 14.62 (SD = 1.72); 25 were birth assigned male (24.0%)
and 79 were birth assigned female (76.0%), which is representative of the typical birth assigned sex
(BAS) ratio of referrals to the service. The stated gender identities of the participants were male (n = 71),
female (n = 23), non-binary/agender (n = 6), and ‘not specified’ (n = 4).
2.3. Measures
2.3.1. Social Responsiveness Scale 2 (SRS-2)
The SRS-2 is a parent-report screening tool that is designed to ascertain the presence and severity
of core behaviours that characterise ASD [32] . It is comprised of 65 questions rated on a 4-point Likert
scale (from 0 = never true to 3 = almost always true) and identifies social impairments in children
across five subscales: Social Awareness, Social Cognition, Social Communication, Social Motivation,
and Autistic Mannerisms. It yields a Total score, and a score for each subscale. Notably, the SRS-2
also generates a DSM-5 severity score, derived from combining two additional subscales; Social and
Communication Impairments, and Restricted and Repetitive Behaviours. In a community population,
the SRS-2 distinguishes between children and adolescents without ASD, and those with clinically
significant levels of ASD traits [34] Ratings are expressed as t-scores (M = 50, SD = 10). t-scores are
classified as being in the ‘normal’ (≤59), ‘mild’ (60–65), ‘moderate’ (66–74) or ‘severe’(≥75) range. While
t-scores of 60 or higher indicate clinically significant ASD symptoms, t-scores of ≥75 are associated
with a categorical ASD diagnosis [35], with a sensitivity of 0.85 and a specificity of 0.75 for generating
a consensual diagnosis [36]. As the emphasis of the current study was the presence of categorical ASD
diagnosis, participants were classified as ‘ASD indicated’ if they had scored in the ‘severe’ range in
the DSM-5 subscale, which is consistent with the methodologies employed in other recent empirical
studies [37,38].
2.3.2. Achenbach Youth Self Report (YSR)
The YSR assesses behavioural and emotional difficulties across multiple domains in adolescents
aged 11 to 18 years of age. It is comprised of 118 items rated on a 3-point Likert scale [39]. A higher
score indicates elevated levels of behavioural and emotional problems. The YSR specifies cut-offs for
borderline and clinical ranges on the following subscales: Anxious/Depressed, Withdrawn/Depressed,
Somatic Complaints, Social Problems, Thought Problems, Attention Problems, Rule-Breaking Behaviour,
and Aggressive Behaviour. A Total score for all behaviours is yielded, in addition to a total
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score for Internalising behaviours (Anxious/Depressed, Withdrawn/Depressed, Somatic Complaints,
Thought Problems) and Externalising behaviours (Social Problems, Attention Problems, Rule-Breaking
Behaviour, Aggressive Behaviour). Where participants had literacy or cognitive difficulties, the YSR
was not completed. To ensure that the current sample was representative of the GDS population,
participants were not excluded from the study on this basis and the other measures were used
in analysis.
2.3.3. Paediatric Quality of Life Inventory (PedsQL)
The PedsQL is a brief standardized instrument that assesses health-related quality of life and
adaptive functioning in children and adolescents and utilises both a self-report and parent-rated
version of the questionnaire [40]. It consists of 23 items rated on a 5-point Likert scale covering four
dimensions of functioning: Physical, Emotional, Social and School Behaviours. A higher score on
the PedsQL indicates better health-related quality of life. Each item is reverse-scored and linearly
transformed on a continuous scale between 0 and 100 (0 = 100, 1 = 75, 2 = 50, 4 = 0. The PedsQL yields
a score for each dimension; a Psychosocial Health Summary Score (comprised of Emotional, Social, and
School functioning), a Physical Health Summary Score (comprised of Physical functioning), and a Total
Score, calculated by summing all the items. The Total score is calculated by the summing all the items
over the number of items answered on all the scales. The child version (8–12 years) and adolescent
version (13–17 years) were both used to ensure developmental appropriateness. The wording and
content for the items on the child and adolescent forms are similar, but the scales remain separate to
allow for developmental differences in cognitive abilities.
3. Results
Of this sample, 77.90% (n = 81) reported a history of any mental health problems, deliberate-self
harming behaviours and/or suicidal intent or attempts, while 11.50% (n = 12) did not report any such
history. Mental health data were missing for 10.58% (n = 11) of participants. At entry to the GDS, 9.62%
(n = 10) of the sample reported a formal diagnosis of ASD; this information was available for 10.58%
(n = 11 of the sample).
Sample demographics (including sex assigned at birth and gender identity) and descriptive
statistics for psychological measures (YSR and PedsQL) are presented in Table 1. Mean scores on the
YSR were high, with the mean t-score for Internalising and Total behaviours within the clinical range.
In this sample, 65.4% (n = 68) of participants fell into the clinical range on Internalising behaviours,
14.4% (n = 15) fell in the clinical range on Externalising behaviours, and 54.8% (n = 57) fell into the
clinical range on Total behaviours.









Other gender identity 4 3.8
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Table 1. Cont.
N M SD
Age at referral 104 14.62 1.72
Age at SRS-2 completion 104 15.49 1.67
SRS-2 Social Awareness 104 57.88 12.17
SRS-2 Cognitive 104 55.95 13.04
SRS-2 Communication 104 58.38 13.10
SRS-2 Motor 104 63.39 14.52
SRS-2 Restricted and Repetitive
Behaviours 102 62.24 13.76
SRS-2 Social Communication 104 59.83 13.54
SRS-2 DSM-5 100 61.77 14.03
SRS-2 Total score 104 60.68 14.06
YSR Internalising t-score 102 67.00 12.83
YSR Externalising t-score 102 54.45 10.19
YSR Total t-store 102 64.08 10.94
PedsQL Physical standardised score 94 69.40 21.52
PedsQL Emotional standardised score 94 47.43 22.16
PedsQL Social standardised score 94 66.86 23.63
PedsQL School standardised score 93 54.84 21.62
PedsQL Psych standardised score 94 55.95 19.77
PedsQL Total standardised score 94 60.60 19.15
Note: BAS = birth-assigned sex, SRS-2 = Social Responsiveness Scale 2, YSR = Youth Self Report, PedsQL = Paediatric
Quality of Life Inventory.
The proportion of participants falling into the ‘normal’, ‘mild’, ‘moderate’, and ‘severe’ ranges
based on SRS-2 scores are presented in Table 2. For SRS-2 Total scores, 51% of the sample fell within
the ‘normal’ range. The remaining 49% of the sample were approximately equally distributed across
the ‘mild’ (16.3%), ‘moderate’ (14.4%) and ‘severe’ (18.3%) clinical ranges. The sample was similarly
distributed on the DSM-5 subscale, with 17.3%, 9.6% and 22.1% of the sample being spread across the
‘mild’, ‘moderate’ and ‘severe’ categories.
Table 2. Proportion of sample falling within each range on the SRS-2 total and subscales.
Within Normal Range Mild Moderate Severe
N % N % N % N %
Total score 53 51.0 17 16.3 15 14.4 19 18.3
Social Awareness 63 60.6 15 14.4 18 17.3 8 7.7
Cognitive 70 67.3 10 9.6 14 13.5 10 9.6
Communication 59 56.7 18 17.3 14 13.5 13 12.5
Motor 41 39.4 18 17.3 23 22.1 22 21.2
Restricted and Repetitive
Behaviours 46 44.2 21 20.2 13 12.5 22 21.2
Social Communication 56 53.8 14 13.5 17 16.3 17 16.3
DSM-5 49 47.1 18 17.3 10 9.6 23 22.1
Note: 2 participants missing Restricted and Repetitive Behaviours score; 4 participants missing DSM-5 score.
Based on the SRS-2 DSM-5 subscale, the sample was partitioned into two groups: participants
who fell in the ‘severe’ range (n = 23; 22.1%) (indicated ASD), and participants who did not fall
within the ‘severe’ range, i.e., were ‘normal’, ‘mild’ or ‘moderate’ (n = 77; 74.0%) (no ASD indicated).
Demographic and descriptive statistics for these two groups are presented in Table 3. Chi-square
analyses indicated no significant group differences on sex assigned at birth or gender. There were
also no statistically significant differences between groups with respect to age at referral (t = 1.16 (98),
p = 0.2) and age at which the SRS-2 was completed in the clinic (t = 0.37, (98), p = 0.7).
Descriptive statistics for the YSR and PedsQL for these two groups are presented in Table 3. Linear
regressions using indicated ASD vs. no ASD indicated as a predictor of continuous psychopathology
outcomes (YSR and PedsQL) were conducted, with sex-assigned at birth, time between assessments
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and age at SRS-2 administration as covariates. These findings are presented in Table 4. Indicated/not
indicated ASD was significantly associated with all subscales of the PedsQL, and all YSR subscales
except Externalising behaviours, suggesting higher levels of mental health difficulties and poorer
quality of life among these children and adolescents with indicated ASD.
Table 3. Demographics, autistic traits, psychopathology and quality of life by indicated/not indicated
ASD on the SRS-2 DSM-5 subscale.
Indicated ASD No ASD Indicated
N % N % p-Value
BAS 0.6
Female 19 82.6 60 77.9
Male 4 17.4 17 22.1
Gender identity 0.3
Female 4 17.4 16 20.8
Male 15 65.2 56 72.7
Non-binary/agender 2 8.7 4 5.2
Other gender identity 2 8.7 1 1.3
N M SD N M SD
Age at referral 23 14.97 1.18 77 14.49 1.87 0.2
Age at SRS-2 completion 23 15.62 1.42 77 15.47 1.78 0.7
YSR Internalising t-score 22 74.00 13.72 76 64.99 12.25 0.004
YSR Externalising t-score 22 56.64 8.56 76 53.80 10.81 0.3
YSR Total t-store 22 69.09 12.22 76 62.68 10.46 0.01
PedsQL Physical standardised score 20 53.28 22.91 71 73.70 19.18 <0.001
PedsQL Emotional standardised score 20 38.25 21.11 71 49.84 22.11 0.04
PedsQL Social standardised score 20 50.75 25.41 71 71.13 21.58 0.001
PedsQL School standardised score 20 44.75 22.39 70 57.71 21.14 0.01
PedsQL Psych standardised score 20 45.25 19.52 71 58.79 19.33 0.007
PedsQL Total standardised score 20 47.59 20.13 71 64.07 17.70 0.001
Note: BAS = birth-assigned sex, SRS-2 = Social Responsiveness Scale 2, YSR = Youth Self Report, PedsQL = Paediatric
Quality of Life Inventory.
We also explored whether indicated/not indicated ASD was predictive of clinically significant
YSR scores. Of those participants in the indicated ASD group, 78.4% (n = 18) also fell into the clinical
range on Internalising behaviours, 13.0% (n = 3) fell into the clinical range on Externalising behaviours,
and 82.6% (n = 19) fell into the clinical range on Total behaviours. Of the participants with no ASD
indicated, 61.0% (n = 47) fell into the clinical range on Internalising behaviours, 15.6% (n = 12) fell
into the clinical range on Externalising behaviours, and 46.8% (n = 36) fell into the clinical range on
Total behaviours. Binary logistic regression analyses were conducted, with membership in the clinical
range on the YSR behaviours as dependent variables and indicated/not indicated ASD as the predictor
(covarying for BAS, time between assessments and the age the SRS was administered). Participants
with indicated ASD were as likely to fall into the clinical range for the YSR Internalising behaviours
(Exp(B) = 2.91 (95% CI = 0.87, 9.74, p = 0.08)) and YSR Externalising behaviours (Exp(B) = 0.84
(95% CI = 0.20, 3.31, p = 0.80)) as those with no ASD indicated. For YSR Total behaviours, the
odds of falling into the clinical range were significantly higher for participants with indicated ASD
(Exp (B) = 7.77 [95% CI = 2.04, 29.56], p = 0.003).
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Table 4. Indicated and no indicated ASD on the SRS-2 DSM-5 subscale predicting psychopathology
and quality of life.
B 95% CIs for B p-Value
YSR Internalising t-score
SRS-2 ASD indicator 8.88 2.82, 14.94 0.005
Age at SRS-2 completion −0.80 −2.34, 0.73 0.30
Birth-assigned sex −4.61 −10.81, 1.59 0.14
Time between SRS-2 and YSR −0.37 −4.20, 3.45 0.85
YSR Externalising t-score
SRS-2 ASD indicator 2.67 −2.30, 7.64 0.29
Age at SRS-2 completion −0.66 −1.92, 0.60 0.30
Birth-assigned sex −4.07 −9.15, 1.02 0.15
Time between SRS-2 and YSR −1.01 −4.14, 2.13 0.53
YSR Total t-score
SRS-2 ASD indicator 6.24 1.06, 11.42 0.019
Age at SRS-2 completion −0.83 −2.14, 0.49 0.21
Birth-assigned sex −5.09 −10.37, 0.21 0.06
Time between SRS-2 and YSR −0.58 −3.85. 2.60 0.73
PedsQL Physical standardised score
SRS-2 ASD indicator −19.83 −29.84, −9.81 <0.001
Age at SRS-2 completion 0.74 −1.69, 3.17 0.55
Birth-assigned sex 13.12 2.84, 23.40 0.013
Time between SRS-2 and PedsQL −1.51 −8.01, 5.00 0.646
PedsQL Emotional standardised score
SRS-2 ASD indicator −10.92 −21.78, −0.06 0.049
Age at SRS-2 completion 1.36 −1.23, 3.99 0.31
Birth-assigned sex 15.20 4.05, 26.35 0.008
Time between SRS-2 and PedsQL −1.75 −8.81, 5.30 0.62
PedsQL Social standardised score
SRS-2 ASD indicator −21.75 −32.98, −10.52 <0.001
Age at SRS-2 completion 0.007 −2.71, 2.73 0.97
Birth-assigned sex 7.07 −4.46, 18.59 0.23
Time between SRS-2 and PedsQL −7.79 −15.08, −0.50 0.037
PedsQL School standardised score
SRS-2 ASD indicator −13.16 −24.10, −2.23 0.019
Age at SRS-2 completion 1.11 −1.55, 3.78 0.41
Birth-assigned sex 8.40 −2.83, 19.63 0.14
Time between SRS-2 and PedsQL −3.39 −10.49, 3.71 0.35
PedsQL Psych standardised score
SRS-2 ASD indicator −13.77 −23.41, −4.14 0.006
Age at SRS-2 completion 1.12 −1.22. 3.45 0.344
Birth-assigned sex 11.02 1.13, 20.91 0.029
Time between SRS-2 and PedsQL −4.18 −10.44, 2.07 0.19
PedsQL Total standardised score
SRS-2 ASD indicator −16.44 −25.47, −7.41 <0.001
Age at SRS-2 completion 1.00 −1.18, 3.19 0.36
Birth-assigned sex 11.75 2.48, 21.02 0.01
Time between SRS-2 and PedsQL −3.31 −9.17, 2.55 0.26
Note: YSR = Youth Self Report, PedsQL = Paediatric Quality of Life Scale.
4. Discussion
Emerging research suggests an overrepresentation of ASD diagnoses and autistic traits in gender
diverse children and adolescents [4–8] compared to general population prevalence estimates [41,42].
To our knowledge, there have been no empirical investigations examining measures of psychological
symptoms and function, and quality of life, in gender diverse young people with ASD. Using data
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from the GENTLE Cohort from the Gender Diversity Service at Perth Children’s Hospital, the primary
objective of the current retrospective chart review was to explore the association between ASD,
psychopathology, and quality of life in gender diverse children and adolescents.
4.1. Autistic Traits in Clinic-Referred Gender Diverse Children and Adolescents
Our first aim was to examine levels of autistic traits in the sample, with a particular focus on
participants scoring in the ‘severe’ range on the SRS-2 DSM-5 subscale ≥75 as an indicator of ASD,
which closely aligns with the DSM-5 diagnostic criteria for ASD [32]. In view of existing research
regarding high rates of ASD and autistic traits in children and adolescents presenting to specialised
gender clinics [4–8], we hypothesised that a larger proportion of the participants would meet the
criteria for ASD compared to estimates from the general population. The results of the current study are
consistent with this hypothesis, with indicated ASD present in 22.1% (n = 23) of the sample. Although
prevalence cannot be determined using SRS-2 scores, this estimate is markedly higher than children
and adolescents thought to have ASD in the general population, with estimates ranging between 1.7%
and 2.47% [41,42].
Notably, 9.62% (n = 10) of the sample reported a formal diagnosis of ASD at the time of clinical
intake, which is also substantially higher than general population prevalence estimates. The discrepancy
between indicated ASD on the SRS-2 (n = 23) and formally diagnosed ASD (n = 10) may be partially
attributed to the retrospective design of the current study, as this information was missing from the
clinical notes of some participants (10.58%; n = 11), and it is possible that some of these participants
had an ASD diagnosis. Not all young people who may have ASD in Western Australia have had
access to specialist ASD diagnosis services. This may be because the diagnosis is not suspected until
adolescence for some young people. For others, it may be because of barriers such as waiting lists
at public services, substantial financial cost at private services, geographical remoteness, or family
reluctance to pursue assessment. Another explanation could be that ASD traits in gender diverse
children and adolescents may be attributed to the wide spectrum of gender diverse behaviours and
expressions, which could result in fewer clinical queries of ASD in these young people.
In addition, given that a substantial proportion of the sample were birth-assigned females (76.0%,
n = 79), another explanation for these findings could be attributed to the effects of BAS on ASD
diagnosis. Drawing from the broader ASD literature, it is well-established that females are much less
likely to be diagnosed with ASD than males, even when symptoms are equally severe [43], with a
reported male-to-female ratio of approximately 4:1 [44]. Females with ASD are thought to be better at
‘camouflaging’ their symptoms through the use of compensatory strategies to mitigate communication
and social difficulties [45,46]. Very little is currently understood about how gender variance influences
ASD expression and clinical identification, but it is possible that gender diverse BAS may use similar
compensatory strategies. However, it is notable that 31.67% of birth-assigned females in the current
sample had indicated ASD (19/60), in contrast to 23.5% in birth-assigned males (4/17). These data
suggest that ASD might be more prevalent in BAS who are gender diverse, or that the birth-assigned
male-to-female ratios of ASD in this group might be closer to 1:1. It is difficult to draw definitive
conclusions based on the small sample size, and further studies are warranted to explore this.
It is noteworthy to mention that an additional 26.9% of participants fell into the ‘mild’ (17.3%, n =
18) and ‘moderate’ (9.6%; n = 10) ranges for the DSM-5 subscale on the SRS-2. Including participants
that fell into the ‘severe’ range, these data indicate that almost half of this gender diverse sample have
some degree of ASD traits. Although previous studies have used an older version of the SRS, which
does not generate a DSM-5 subscale score, Total SRS scores from these studies indicate that between
44.9% and 54.2% of clinic-referred gender diverse children and adolescents fall within this spectrum of
scores [16,33], which aligns with our findings.
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4.2. Associations between ASD, Psychopathology and Quality of Life
Our secondary aim was to explore psychological outcomes and quality of life in the group with
indicated ASD compared to the participants with no ASD indicated. As ASD and gender diversity
are both independent risk factors for psychopathology and lower quality of life outcomes, it was
hypothesised that the ASD group would experience significantly poorer mental health (i.e., elevated
YSR scores) and quality of life (i.e., lower PedsQL scores) than participants without ASD. With respect
to YSR scores, this hypothesis was partially supported; we demonstrated that indicated ASD was a
significant predictor of Internalising behaviours. Indicated ASD was also found to be a significant
predictor of overall behavioural problems, whereby participants from this group were almost 8 (7.77)
times more likely to fall within the clinical range for the Total subscale of the YSR than those with
no ASD indicated. There were no group differences on Externalising behaviours, which suggests
that ASD expression in gender diverse populations may be less likely to be associated with clinical
externalising problems.
It should be noted that both groups had clinically elevated mean scores for the Internalising scale
of the YSR (indicated ASD [M = 74.00, SD = 13.72]; no ASD indicated [M = 64.99, SD = 12.25]). This
is consistent with the established finding of high rates of psychopathology in gender diverse young
people, including internalising psychiatric disorders (e.g., mood disorders, anxiety disorders) [8,24,26].
Collectively, however, the current findings support the notion that clinic-referred gender diverse
children and adolescents with co-occurring ASD comprise an especially vulnerable group that are at
marked risk of mental health difficulties, particularly internalising psychopathology.
Indicated ASD was also a significant predictor of scores on all subscales on the PedsQL. This
suggests that gender diverse participants with ASD have a reduced quality of life across their physical
health, social and emotional wellbeing, and school functioning compared to gender diverse participants
without indicated ASD. These findings complement studies that indicate high levels of stigma and
prejudice in gender diverse young people with co-occurring ASD, who receive less parental support
when disclosing concerns about gender identity [31]. The finding of reduced quality of life indicators
in this high-risk group underscore the importance of providing psychosocial support to gender diverse
young people with co-occurring ASD and their families.
4.3. Implications
The current investigation is novel in several respects. To our knowledge, this is the first study
to estimate the proportion of children and adolescents referred to an Australian gender clinic with
‘indicated ASD’, as indexed by a brief screening measure. The distribution of ASD traits reported
here are similar to those reported from other countries that used the SRS in child and adolescent
gender clinics [16,33]. These findings highlight the similarities between clinic-referred gender diverse
cohorts internationally, an area which has been relatively unexplored. Given the high rates of ASD and
autistic traits in these samples, it is pivotal that there is sufficient education amongst health providers
working with gender diverse young people, particularly familiarity with current guidelines around
this co-occurrence [13]. The current study is also the first to examine the associations between ASD,
psychopathology and quality of life in a clinically derived gender diverse sample. Awareness of
difficulties that are common in this subgroup, particularly internalising problems, are also important to
inform thorough assessment and personalised care planning, including access to evidence-based mental
health care, which can sit alongside gender-affirming medical treatment to support overall wellbeing.
The high proportion of the current sample with significant autistic traits relative to self-reported
diagnoses indicates that there may be individuals who have not previously been identified. As the
GDS does not have capacity and resources to formally diagnose ASD, the inclusion of the SRS-2 as
a brief screening measure for suspected ASD is an important addition to our specialised child and
adolescent gender clinic assessment pathway, and aligns with current guidelines [13]. Although it
is not a diagnostic measure, it is effective and convenient in in flagging potential ASD, which may,
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in turn, help to inform clinical assessment and treatment decisions, as well as prompting referral for
formal ASD assessment.
4.4. Limitations
A limitation of the current study concerns the methodology of evaluating ASD diagnosis. Although
the SRS-2 has strength in being aligned with the DSM-5 criteria for ASD, it is a screening tool for
the presence and severity of autism traits and an indication of a potential diagnosis only. It is
therefore possible that individuals who scored in the ‘moderate’ or even ‘mild’ range of the SRS-2
may meet diagnostic criteria for ASD if formally assessed. The SRS-2 is a parent report instrument,
with no youth self-report component available, and no structured direct clinical assessment of autism
spectrum characteristics.
It is also necessary to acknowledge that the individuals referred to the GDS are not representative
of all gender diverse children and adolescents in Australia, in that the vast majority of the young
people referred to the GDS have some degree of support and acceptance from at least one parent or
guardian to facilitate referral, and are involved in the ongoing assessment and treatment. Gender
diverse youth who are estranged from family (who have experienced non-acceptance or rejection) are
likely to experience more severe mental health distress and may differ from this study population [11].
4.5. Future Research
There are several avenues for future studies that could be considered. Future researchers should
use the findings of this study to inform the development and evaluation of best clinical practice
guidelines in Australia. For example, studies could evaluate whether increasing clinicians’ knowledge
of ASD in the gender diverse population improves patient care experience and outcomes. This will
aim to improve the clinical care provided to gender diverse young people to ensure their specific
needs are being catered for. Additionally, future studies should seek to investigate potential causal
factors underlying this co-occurrence. Such data can help to improve our understanding of the
interaction between gender diversity and ASD, and similarly help to inform the care being provided to
this population.
Finally, it should be noted that although the discourse in the literature regarding the co-occurrence
of ASD traits and gender diversity is often one of difficulties, deficits and complexities, our clinical
experience working with this group of young people is that great strengths are often evident. These
include, but are not limited to creativity, originality and personal integrity, a passion for advocacy, and
notable academic, artistic, musical and literary talents. These observations could also guide further
research exploring the characteristics of this population.
4.6. Conclusions
This study expanded on previous research to replicate the finding of higher levels of autistic
traits and ASD in a clinic-referred gender diverse sample in Australia. We found that gender diverse
children and adolescents with indicated ASD comprise an especially vulnerable group that are at
marked risk of mental health difficulties, particularly internalising disorders, and poor quality of life.
These findings should be considered when developing best practice for working with gender diverse
young people with ASD to ensure that their health care meets their unique needs.
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